2 unknown, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 2, Completed 1 |
Follow Comirnaty: new trials by email Literature Review of Comirnaty trials Research Report on Comirnaty
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 RQ3013, Comirnaty - COVID-19 | Phase 1 | Unknown | Walvax Biotechnology Co., Ltd. | 120 | 2022-12-01 | 2022-11-18 |
| A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19 RQ3013, Comirnaty - COVID-19 | Phase 1 | Unknown | Walvax Biotechnology Co., Ltd. | 120 | 2022-07-01 | 2022-05-31 |
| Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 MVA-SARS-2-S vaccinations (days 0 & 28), Comirnaty - Covid19 | Phase 1 | Completed | Universitätsklinikum Hamburg-Eppendorf | 30 | 2020-10-05 | 2021-11-05 |
COVID-19 (3)
Walvax Biotechnology Co., Ltd. (2) · Universitätsklinikum Hamburg-Eppendorf (1)
Germany (1)
Lin Yuan (2) · Marylyn M Addo, MD (1)